Paul Chamberlin

Dr. Chamberlin has significant experience in cardiovascular therapeutic research and clinical development. Prior to joining Ventrix in 2011, He was VP of Medical Development at Sequel Pharmaceuticals, and prior to that at NovaCardia, where he led research and clinical development of cardiac drugs for the treatment of heart failure and atrial fibrillation. Prior to NovaCardia, Dr. Chamberlin served in various positions at EPIX Pharmaceuticals, most recently as Executive Medical Director. He also worked in the Healthcare Practice of Arthur D. Little and the biotechnology division of Rhone-Poulenc-Rorer. Dr. Chamberlin earned a B.A. in Biology from the University of Pennsylvania and completed his M.D. at Boston University.